leadf
logo-loader
viewWe Company

WeWork gets more financing from SoftBank after membership numbers hit by pandemic

Revenues were lower and cash burn was higher in the second quarter

We Company - WeWork gets more financing from SoftBank after membership numbers hit by pandemic

WeWork’s parent company has raised US$1.1bn in new debt from majority owner SoftBank Group after the second quarter was hit by the coronavirus pandemic.

The shared office provider reported a reduction in revenue and increase in cash burn from the first quarter to the second. 

Turnover in the second quarter was US$882mln, up 9% year on year but down around 20% from the first, according to an email to staff from WeWork’s chief financial officer Kimberly Ross, Reuters reported, as customer numbers shrank by 12% to 612,000 quarter on quarter.

Cash burn US$671mln during the three months to end-June, almost 40% higher than the first quarter’s US$482mln.

However, the second quarter’s cash burn included US$116mln of restructuring costs as, under the Japanese investment giant’s influence, the group’s looks to continue reducing staff numbers by around a fifth and temper the pace of expansion.

“Our early efforts to become a more streamlined, cash-conscious organization puts us in a better position to adapt quickly, navigate new realities and deliver our future business objectives,” said Ross in the memo.

Including the new financing, the We Company coffers are still bulging with US$4.1bn in cash and other commitments.

Chairman Marcelo Claure recently said WeWork was on track to be positive cash flow in 2021. 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma presents at the Proactive One2One virtual conference

Amryt Pharma's LON:AMYT) Rory Nealon presents at the Proactive One2One virtual conference. Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases. The company...

1 day, 2 hours ago

2 min read